Historique de carrière de Kenneth Bartizal
Anciens postes connus de Kenneth Bartizal
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 04/06/2007 | - |
| MERCK & CO., INC. | Directeur/Membre du Conseil | 01/01/2007 | 01/04/2007 |
| Corporate Officer/Principal | 01/05/1987 | 01/04/2007 | |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/1988 | 01/01/1988 |
| Kirksville College of Osteopathic Medicine, Inc. | Corporate Officer/Principal | 01/01/1983 | - |
| Truman State University | Corporate Officer/Principal | 01/01/1983 | - |
| CIDARA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2014 | - |
Formation de Kenneth Bartizal
| University of Notre Dame | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Corporate Officer/Principal | 6 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Kenneth Bartizal
- Expérience
